Technology

Cytune leverages a scientific breakthrough (trans-presentation mechanism of a critical immune factor: IL-15) to develop innovative versions of immunotherapeutic agents

• Cytune conceives and develops immunotherapeutic agents for fighting cancer (priority) and infectious diseases
• Axis n°1: Immunostimulatory agents (Best-in Class category – Lead program): CYP0150
• Axis n°2: New generation of mAbs (conjugated mAbs – R&D Platform)
• Cytune provides competitive early-stage products/technology platforms for large pharma/biotech players facing major R&D pipeline issues

Cancer immunotherapy: reset, restore & activate the defeated antitumor immune system

Interleukin plays a unique role in humans and is potentially a major asset in therapy